肝肾移植患者西罗莫司血药浓度在电化学发光分析平台的分析性能评价

Abstract
Figure/Table
References
Related Citation (3)

Download: PDF (1401 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS)

Abstract Objective To evaluate the performance of whole blood Sirolimus concentration analysis on Roche Cobas E411 detection platform in liver and kidney transplant patients. Methods A total of 100 patients with organ transplantation who came to the Third Medical Center of Chinese PLA General Hospital from January 2022 to October 2022 were selected as research objects. Among them, 47 patients underwent liver transplantation and 53 patients underwent kidney transplantation. The analytical performance of Sirolimus was evaluated on Roche cobas e411, including in-batch precision, inter-batch precision and accuracy. Meanwhile, the comparability of sirolimus on the Roche cobas e411 and Abbott architect i1000sr platforms was evaluated by using the whole blood samples of clinical liver and kidney transplanters, and correlation analysis was performed. Results The intra-lot precision of the three levels of quality control materials were 1.45%, 1.25% and 1.09%, and the inter-lot precision were 4.18%, 2.08% and 2.36%, respectively, which were lower than the precision requirements claimed by the manufacturer. Accuracy sample concentration levels from 5 ng/ml to 30 ng/ml were within the permissible range. There was a significant positive correlation between sirolimus concentration in 100 transplant subjects by Roche cobas e411 and Abbott architect i1000sr, and the correlation coefficient (R²) was 0.9072. Subsequently, sirolimus results were also positively correlated between the two analysis systems in liver and kidney transplant patients, with R² of 0.9322 and 0.83, respectively. Conclusions Sirolimus is characterized by excellent analytical performance on cobas e411 chemiluminescence analysis platform, and good comparability of Sirolimus between Roche and Abbott in the detection of clinical samples for liver and kidney transplantation patients, which lays a foundation for the early analysis of Sirolimus in the mutual recognition of results between laboratories.

Key words： Sirolimus Rapamycin chemiluminescence analysis platform analytical performance evaluation

Received: 02 January 2023

ZTFLH:

R392.4

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	LI Yingli
	MA Xueping
	ZHANG Jing
	LIU Lanlan
	LU Wenjing
	HAO Nan
	ZHANG Cui

Cite this article:

LI Yingli,MA Xueping,ZHANG Jing等. Evaluation of blood concentration of Sirolimus in liver and kidney transplants by electrochemical luminescence analysis platform[J]. Med. J. Chin. Peop. Armed Poli. Forc., 2023, 34(3): 217-220.

URL:

http://journal08.magtechjournal.com/Jwk_wjyx/EN/ OR http://journal08.magtechjournal.com/Jwk_wjyx/EN/Y2023/V34/I3/217

[1]	Lamming D W. Inhibition of the mechanistic target of rapamycin (mTOR)-rapamycin and beyond [J]. Cold Spring Harb Perspect Med, 2016, 6(5): a025924.
[2]	O'Shea A E, Valdera F A, Ensley D, et al. Immunologic and dose dependent effects of rapamycin and its evolving role in chemoprevention [J]. Clin Immunol, 2022, 245: 109095.
[3]	Fan G H, Zhang C Z, Gao F Q, et al. A mixed blessing for liver transplantation patients - rapamycin [J]. Hepatobiliary Pancreat Dis Int, 2023,22(1): 14-21.
[4]	Panackel C, Mathew J F, Fawas N M, et al. Immunosuppressive drugs in liver transplant: an insight [J]. J Clin Exp Hepatol, 2022, 12(6): 1557-1571.
[5]	Gluck M, Hodak E, Davidovici B. Mammalian target of rapamycin inhibitors for prolonged secondary prevention of nonmelanoma skin cancer in solid organ transplant recipients [J]. Dermatol Ther, 2022, 35(8): e15649.
[6]	廖珂,敖建华,赵冠人,等. 汉族肾移植受者稳定期CYP3 A5*3基因多态性与血西罗莫司浓度的相关性 [J]. 中华器官移植杂志, 2013,5(34): 260-264.
[7]	Candela-Boix M R, Ramón-López A, Nalda-Molina R, et al. Population pharmacokinetics models of sirolimus in renal transplant patients: a systematic review [J]. Farm Hosp, 2021, 45(7): 77-83.
[8]	Zhang G, Duan B, Li G. mTORi-based immunosuppression reduces HCC recurrence at the expense of increased adverse side effects: a systematic review and meta-analysis [J]. Clin Transplant, 2022, 36(12): e14823.
[9]	Bruss Z, Farook S, Shah S, et al. Sirolimus-induced rash in a kidney transplant patient [J]. Eur J Case Rep Intern Med, 2022, 9(9): 003565.
[10]	Arya P, Prickett KK, Raol N, et al. Sirolimus-induced pulmonary hemorrhage of an infant with massive cervicofacial lymphatic malformation: a case report [J]. Int J Pediatr Otorhinolaryngol,2023,164: 111404.
[11]	邵琨,陈冰,周佩军. 免疫抑制剂细胞内浓度测定的研究进展 [J]. 器官移植, 2021, 12(4): 489-495.
[12]	任相霖,陈璐,张远,等. 药物基因多态性对肾移植受者西罗莫司血药浓度影响系统评价 [J]. 医药导报, 2022, 41(4): 449-457.
[13]	吴中豪,龚子珊,姜小梅,等. 液质联用法同时测定干血斑中环孢菌素A、西罗莫司、他克莫司和依维莫司药物浓度 [J]. 分析仪器, 2021, 234(1): 11-18.
[14]	王洪良,孙煦勇,董建辉,等. 西罗莫司应用于肝癌肝移植后疗效的系统评价 [J]. 中华器官移植杂志, 2018, 39(7): 418-424.
[15]	Forns X, Navasa M. Liver transplant immunosuppression during the covid-19 pandemic [J]. Gastroenterol Hepatol, 2020 ,43(8):457-463.
[16]	陈小娟,黄晓宁,李勇. 西罗莫司对比他克莫司用于肾移植后抗排异疗效和安全性的Meta分析 [J]. 中国药房, 2016, 27(27): 3821-3824.
[17]	KAKHI, SORAYYA, PHANISH, et al. Dilated cardiomyopathy in an adult renal transplant recipient: recovery upon tacrolimus to sirolimus switch: a case report [J]. Transpl P, 2020, 52(9): 2758-2761.
[18]	Grigg S, Gow P, Yeomans N. Sirolimus in liver transplant recipients with hepatocellular carcinoma [J]. J Invest Surg, 2020, 33(4): 389-390.
[19]	Naik MG, Jürgensen JS, Arns W, et al. Determinants of successful use of sirolimus in renal transplant patients [J]. Transpl P, 2020, 52(10): 3103-3111.
[20]	Xue E, Lorentino F, Clerici D, et al. Coadministration of letermovir and sirolimus in allogeneic hematopoietic cell transplant recipients [J]. Bone Marrow Transplant, 2022, 57(1): 128-130.